Skip to content Skip to navigation

A dual receptor-targeted (DRT) radiation nanomedicine labeled with 177Lu is more potent for killing human breast cancer cells in vitro that co-express HER2 and EGFR than single receptor-targeted (SRT) radiation nanomedicines

TitleA dual receptor-targeted (DRT) radiation nanomedicine labeled with 177Lu is more potent for killing human breast cancer cells in vitro that co-express HER2 and EGFR than single receptor-targeted (SRT) radiation nanomedicines
Publication TypeJournal Article
Year of Publication2020
AuthorsYook, S, Cai, Z, Jeong, JJ, Lu, Y, Winnik, MA, Pignol, J-P, Reilly, RM
JournalMol. Pharmaceutics
Volume17
Pagination1226–1236
DOI10.1021/acs.molpharmaceut.9b01259